Welcome to our dedicated page for BIOAB news (Ticker: BIOAB), a resource for investors and traders seeking the latest updates and insights on BIOAB stock.
The BIOAB news page on Stock Titan provides updates and press releases related to BioArctic AB, a Swedish research-based biopharma company focused on neurodegenerative diseases. Much of the company’s news centers on its antibody Leqembi (lecanemab) for early Alzheimer’s disease and its long-term collaboration with Eisai and other partners.
Investors and followers of BIOAB can find news about clinical data presentations, such as new analyses from Phase 3 studies, long-term treatment findings, and real-world evidence from registries and observational studies. Recent communications highlight presentations at scientific meetings like the Clinical Trials on Alzheimer’s Disease (CTAD) conference, where Eisai, as BioArctic’s partner, shares results on lecanemab’s long-term effects, safety, and different administration approaches, including subcutaneous and intravenous dosing.
Company news also covers the broader development program around lecanemab, including ongoing studies like AHEAD 3-45 in preclinical Alzheimer’s disease and the Tau NexGen clinical study for dominantly inherited Alzheimer’s disease. Updates may describe how lecanemab targets aggregated soluble protofibril and insoluble forms of amyloid-beta and discuss findings from real-world clinical practice and post-marketing studies.
By following this news page, readers can monitor how BioArctic’s collaborations, clinical programs and technology platforms, such as its BrainTransporter™ technology, progress over time. This makes the BIOAB news feed a useful reference for those tracking scientific, clinical and partnership developments related to BioArctic and its Alzheimer’s and other neurodegenerative disease projects.
BioArctic (Nasdaq Stockholm: BIOA B) issued 20,200 new Class B shares in August 2026 following the exercise of 20,200 stock options from the 2019/2028 program approved on May 9, 2019. As of August 31, 2026, BioArctic had a total of 88,744,685 shares outstanding, comprising 74,344,689 listed Class B shares and 14,399,996 unlisted Class A shares. Class A shares carry ten votes per share and Class B shares one vote per share, giving a total of 218,344,649 votes in the company.
BioArctic (Nasdaq Stockholm: BIOA B) reported that partner Eisai presented interim real-world data from the three-year LEADER study of Leqembi in early Alzheimer's disease at AAIC 2026. Among 427 evaluable patients treated for an average of 17 months (mean 520 days, 26 doses), 82.5% remained stable or improved in disease stage, with 75.9% stable and 6.6% improving from mild AD dementia to MCI due to AD. Results were consistent across sex, race, ethnicity and APOE genotype, and nearly 87% of patients chose to remain on treatment.
In 155 patients on once-every-four-weeks IV maintenance, about 81% were stable or improved, while 12 of 14 on weekly SC maintenance maintained stage. Overall safety was described as consistent with the US FDA-approved label; ARIA occurred in 12.3% of patients, mostly asymptomatic and mild, with no new ARIA-E events, macrohemorrhages or intracerebral hemorrhages >1 cm during IV maintenance.
BioArctic (Nasdaq Stockholm: B) announced that its partner Eisai presented new data at AAIC 2026 in London showing the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) achieved pharmacokinetic exposure comparable to the approved IV initiation regimen in early Alzheimer's disease.
Once-weekly 500 mg SC-AI was bioequivalent to IV 10 mg/kg every two weeks, with an exposure ratio of 104% (90% CI: 99.1%–109%), and consistent results across body-weight groups, supporting a fixed-dose regimen. Clinical and biomarker outcomes, including amyloid PET, CDR-SB and ARIA-E incidence, were described as driven by lecanemab exposure rather than administration route.
The SC-AI formulation showed a safety profile generally aligned with IV Leqembi, with mostly localized injection reactions, low anti-drug antibody incidence of 1.4% and no neutralizing antibodies. Early clinical practice data from two US centers indicated slower cognitive decline or stable cognition in treated patients, plus high patient and care partner satisfaction, convenience and willingness to recommend treatment.
BioArctic (Nasdaq Stockholm: BIOA B) held its AGM on 28 May 2026 and approved the 2025 income statement and balance sheet, a dividend of SEK 2 per share with record date 1 June 2026, and discharge of the board and CEO.
Shareholders re-elected six directors, elected two new members, and re-elected the chair. The AGM authorised the board to issue new shares, warrants and convertibles of up to 10% of share capital, adopted a three-year PSU incentive program of up to 235,000 units with related hedging, and updated senior executive remuneration guidelines.
BioArctic (Nasdaq: B) published its Annual Report 2025, with the Sustainability Report and Corporate Governance Report integrated into the document. The company highlights a breakthrough Alzheimer’s drug now on the global market, several licence agreements, a broad pipeline and record-high profits in 2025.
The report aligns sustainability reporting with the European CSRD and ESRS frameworks and is available for download from the company's investor website.
BioArctic (Nasdaq: B) announced that partner Eisai will present new data on lecanemab (Leqembi) at the CTAD conference in San Diego, Dec 1–4, 2025.
Presentations cover long‑term treatment analyses, estimated time savings over 10 years, safety and pharmacokinetics for a subcutaneous initiation option, effects on soluble Aβ protofibrils, and real‑world registry findings including ALZ‑NET and a Japanese post‑marketing study.